Briacell Therap (NASDAQ:BCTX – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Briacell Therap and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Briacell Therap | N/A | -153.53% | -129.26% |
| Pharming Group | 3.30% | 4.64% | 2.55% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Briacell Therap | N/A | N/A | -$26.31 million | ($7.92) | -0.50 |
| Pharming Group | $376.13 million | 2.53 | $2.85 million | $0.16 | 84.16 |
Pharming Group has higher revenue and earnings than Briacell Therap. Briacell Therap is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Briacell Therap has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Briacell Therap and Pharming Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Briacell Therap | 1 | 0 | 0 | 0 | 1.00 |
| Pharming Group | 1 | 1 | 3 | 0 | 2.40 |
Pharming Group has a consensus target price of $38.33, indicating a potential upside of 184.69%. Given Pharming Group’s stronger consensus rating and higher probable upside, analysts clearly believe Pharming Group is more favorable than Briacell Therap.
Summary
Pharming Group beats Briacell Therap on 11 of the 13 factors compared between the two stocks.
About Briacell Therap
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for Briacell Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therap and related companies with MarketBeat.com's FREE daily email newsletter.
